AVAX Technologies, Inc.
(Public, OTC: AVXT.PK)
The successful completion of these goals has paved the way for a fresh and optimistic 2008 and 2009 for AVAX. Having raised $10M in equity financing, and $1.2M in a collaboration of CTCA on the OVARIAN trials (Ovax), dilution should be out of the question for the remainder of 2010. Despite all of this, there remains one main reason which makes AVAX a solid company: their pipeline which targets some of the fastest growing markets within the biotech medical industry. MVax is aiming towards a $775M Melanoma treatment market by 2010, while Ovax looks to enter a potential Ovarian cancer drug market of $1.6B by 2016. Moreover, AVAX' currently trades at a highly undervalued estimated market cap of 27.10M when comparred to a similar cancer treatment company in Cell Therapeutics (NASDAQ:CTIC), which is sitting at roughly 627.11M market cap without any drugs currently being approved by the FDA. 2010 should prove to be an eventful year for this up and coming rising small cap biotech. MVax® is AVAX's lead product candidate and it is currently in an International Phase III Registration trial with centers in the U.S., Europe and Israel. To date over 600 patients have been treated with the AC Vaccine Technology.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is an internationally integrated biotechnology company focused on developing and commercializing its AC Vaccine® technology for the treatment of cancer. The AC Vaccine Technology is an immunotherapeutic treatment that educates the patient's immune system to recognize cancer cells as foreign through the process of haptenization. Haptenization is a re-education of the immune system through a chemical modification of antigens on the cancer cell which allows for the development of an immune response to cancer cells that were previously ignored by the immune system. To produce AVAX's AC Vaccine cancer cells are obtained from tumors excised during routine surgery. These cells are then treated with the hapten dinitrophenyl (DNP). Injection of the DNP-modified vaccine induces an immune response against native cancer cells in the patient's body, and, under the best of circumstances, kills them or controls their growth.
AVAX is headquartered in Philadelphia, PA with operations in Lyon, France where it has established a cGMP manufacturing facility that is currently producing the vaccines for the ongoing Phase III Registration trial of MVax®, the AC Vaccine for Melanoma.
About AVAX's Vaccine Treatment Technology
*All information provided from the company's website at http://www.avax-tech.com
AVAX is an internationally integrated development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. Their vaccine consists of autologous (the patient's own) cancer cells that have been treated with a chemical ("haptenized") to make them more visible to the patient's immune system. AVAX refers to their cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine.
The AC Vaccine is processed directly from the patients tumor. The tumor is broken down to the basic cancer cells. These cancer cells undergo a series of treatment steps and then the cells are modified with DNP, which attaches to the proteins on the surface of the cells.